Beneficial effect of an antibody against interleukin-2 receptor (daclizumab) in an experimental model of hepatocyte xenotransplantation

Table 1 Survival analysis and survival rate

	Median (95% CI)1	n (%)2
FHF	2 (1-2)	0/13 (0)
XenoTx	6 (3-9)a	4/14 (28.6)e
XenoTx + CsA	11 (8-14)ac	10/14 (71.4)ef
XenoTx + Dmab	15 (14-15)ac	13/14 (92.9)ef
XenoTx + Dmab + CsA	13 (12-15)ac	10/13 (76.9)ef

¹Kaplan Meier-Log-rank test:

^aP < 0.05 vs FHF;

^cP < 0.05 vs XenoTx.

²Chi-square, Fisher’s exact test:

^eP < 0.05 vs FHF;

^fP < 0.05 vs XenoTx. FHF: fulminant hepatic failure.

Table 2 Histopathological analysis

	Median score (Min-Max)
FHF	2 (2-5)a
XenoTx	1 (0-3)
XenoTx + CsA	1 (1-5)a
XenoTx + Dmab	0 (0-3)
XenoTx + Dmab + CsA	3 (0-3)a

Kruskal-Wallis: P = 0.001; Mann-Whitney:

^aP < 0.05 vs Dmab. FHF: fulminant hepatic failure.

Table 3 Biochemical analysis

	SGOT1	SGPT2	Direct TBi3
	Median (Min-Max)	Median (Min-Max)	Median (Min-Max)
FHF	565.00 (3-1077)	257.00 (111-759)	0.03 ( 0.02-0.08)e
XenoTx	143.00 (83-154 )a	60.00 ( 58-67)c
XenoTx + CsA	58.00 (43-88)a	112.00 (85-183)c	0.03 (0.02-0.05)e
XenoTx + Dmab	246.00 (101-365)a	92.00 (50-339)c	0.02 (0.00-0.10)
XenoTx + Dmab + CsA	142.50 (98-247)a	58.50 (41-77)c	0.01 (0.00-0.03)

¹Kruskal-Wallis P < 0.0005; Mann-Whitney:

^aP < 0.05 vs FHF;

²Kruskal-Wallis: P < 0.0005; Mann-Whitney:

^cP < 0.05 vs FHF;

³Kruskal-Wallis: P = 0.044; Mann-Whitney:

^eP < 0.05 vs XenoTx + Dmab + CsA. TBi: total bilirubin; FHF: fulminant hepatic failure; CsA: cyclosporin.